Skip to main content

Multiple Myeloma

Multiple Myeloma, Oncology
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
The Evolution of Survivorship Care in Multiple Myeloma
John A. Welz, MPH
Read More
Multiple Myeloma, Oncology
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma, Oncology
Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
Dana Taylor
Read More
Multiple Myeloma, Oncology
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
Dana Taylor
Read More
Multiple Myeloma, Oncology
Consistent Benefit Over Time in Elotuzumab Studies
Dana Taylor
Read More
Multiple Myeloma, Oncology
Daratumumab Improves Overall Survival in Multiple Myeloma
Dana Taylor
Read More
Multiple Myeloma, Oncology
Pomalidomide plus Low-Dose Dexamethasone Combination Likely to Be Cost-Effective
Read More
Page 3 of 6
Results 21 - 30 of 53